Literature DB >> 18684975

Molecular mechanisms of TGF beta receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506.

El-Sayed Akool1, Anke Doller, Andrea Babelova, Wasiliki Tsalastra, Kristin Moreth, Liliana Schaefer, Josef Pfeilschifter, Wolfgang Eberhardt.   

Abstract

The calcineurin inhibitor (CNI)-induced renal fibrosis is attributed to an exaggerated deposition of extracellular matrix, which is mainly due to an increased expression of TGFbeta. Herein we demonstrate that the CNI cyclosporin A and tacrolimus (FK506), independent of TGFbeta synthesis, rapidly activate TGFbeta/Smad signaling in cultured mesangial cells and in whole kidney samples from CNI-treated rats. By EMSA, we demonstrate increased DNA binding of Smad-2, -3, and -4 to a cognate Smad-binding promoter element (SBE) accompanied by CNI-triggered activation of Smad-dependent expression of tissue inhibitor of metalloprotease-1 (TIMP-1) and connective tissue growth factor. Using an activin receptor-like kinase-5 (ALK-5) inhibitor and by small interfering RNA we depict a critical involvement of both types of TGFbeta receptors in CNI-triggered Smad signaling and fibrogenic gene expression, respectively. Mechanistically, CNI cause a rapid activation of latent TGFbeta, which is prevented in the presence of the antioxidant N-acetyl cysteine. A convergent activation of p38 MAPK is indicated by the partial blockade of CNI-induced Smad-2 activation by SB203580; conversely, both TGFbeta-RII and TGFbeta are critically involved in p38 MAPK activation by CNI. Activation of both signaling pathways is similarly triggered by reactive oxygen species. Finally, we show that neutralization of TGFbeta markedly reduced the CNI-dependent Smad activation in vitro and in vivo. Collectively, this study demonstrates that CNI via reactive oxygen species generation activate latent TGFbeta and thereby initiate the canonical Smad pathway by simultaneously activating p38 MAPK, which both synergistically induce Smad-driven gene expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684975     DOI: 10.4049/jimmunol.181.4.2831

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Norcantharidin, a protective therapeutic agent in renal tubulointerstitial fibrosis.

Authors:  Ying Li; Yan Ge; Fu You Liu; You Ming Peng; Lin Sun; Jun Li; Qiong Chen; Yan Sun; Kun Ye
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

2.  Increased Advanced Oxidation Protein Products Generation by Cyclosporine-A and Angiotensin II in Human Gingival Fibroblasts - Ex-vivo Study.

Authors:  Suresh Ranga Rao; Rajasekaran Subbarayan; Supraja Ajitkumar; Dinesh Murugan Girija
Journal:  J Clin Diagn Res       Date:  2017-01-01

3.  Non-immunologic allograft loss in pediatric kidney transplant recipients.

Authors:  Isa F Ashoor; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2018-02-26       Impact factor: 3.714

4.  Cyclosporin A inhibits colon cancer cell growth independently of the calcineurin pathway.

Authors:  Miriam B F Werneck; Eugênio Hottz; Patricia T Bozza; João P B Viola
Journal:  Cell Cycle       Date:  2012-09-19       Impact factor: 4.534

5.  Fibrocytes can be reprogrammed to promote tissue remodeling capacity of dermal fibroblasts.

Authors:  Abelardo Medina; Aziz Ghahary
Journal:  Mol Cell Biochem       Date:  2010-06-20       Impact factor: 3.396

Review 6.  Molecular aspects of cyclophilins mediating therapeutic actions of their ligands.

Authors:  Andrzej Galat; Jacqueline Bua
Journal:  Cell Mol Life Sci       Date:  2010-07-04       Impact factor: 9.261

7.  Procarcinogenic effects of cyclosporine A are mediated through the activation of TAK1/TAB1 signaling pathway.

Authors:  Jianmin Xu; Stephanie B Walsh; Zoe M Verney; Levy Kopelovich; Craig A Elmets; Mohammad Athar
Journal:  Biochem Biophys Res Commun       Date:  2011-02-17       Impact factor: 3.575

8.  The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studies.

Authors:  Samar Hamdy; Azita Haddadi; Anooshirvan Shayeganpour; Aws Alshamsan; Hamidreza Montazeri Aliabadi; Afsaneh Lavasanifar
Journal:  AAPS J       Date:  2011-02-19       Impact factor: 4.009

Review 9.  Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.

Authors:  Andrzej Galat
Journal:  Cell Mol Life Sci       Date:  2012-12-08       Impact factor: 9.261

10.  Nox2 is a mediator of chronic CsA nephrotoxicity.

Authors:  A Djamali; S Reese; O Hafez; A Vidyasagar; L Jacobson; W Swain; C Kolehmainen; L Huang; N A Wilson; J R Torrealba
Journal:  Am J Transplant       Date:  2012-05-08       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.